The Biotechnology Company
Cannbotech
+4.63%
Base:4,705
opening:4,747
High:5,247
low:4,747
change:565,893
Page Quote News Graphs Company Profile Recommendations
More articles on the subject:
The developer of a botanical drug based on the extraction of substances from the ciatus striatus fungus and extraction of active ingredients from the cannabis plant reports that in an experiment conducted on a cell model, the substance extracted from the fungus eliminated 100% of pancreatic cancer cells relatively selectively and without damaging normal cells. This is 5 times the efficiency shown by the original extraction. At the active concentration on pancreatic cancer cells no damage to the healthy cells was observed. The active ingredients extracted from cannabis (cannabinoids) caused mortality of over 80% of pancreatic cancer cells.
Cannbotech expects to complete the feasibility study phase within 12 months, by mid-2023, at the end of which it will work to create a development collaboration with a large pharma company to approve a drug with the FDA. As part of the next milestones in the development process, the company plans to test both the mechanism of action of killing cancer cells by extracts and the combined anti-cancer efficacy of the fungus and cannabinoids together, in cells and animals.
Approval of a botanical drug should be quicker, in the company’s opinion, than a standard drug approval. The experiment was conducted after the first milestone was completed, which was the adaptation of growing methods and extraction of the fungus to the FDA protocol. In addition, the anti-cancer activity of the new fungal extract and the cannabinoid composition developed by Cannabotek on pancreatic cancer were examined.
If you want to specialize in the capital market and have a big head and motivation, you can suit us.
The job can be part-time; Flexibility in working hours; Work from home too
Priority (optional) for writing experience and basic familiarity with the capital market.
Leave details and we will get back to you
Thank you for leaving details, we will try to get back to you soon
The development of the drug began several months ago, after Kanbotek received global and exclusive use rights for patents created in a study by Prof. Fouad Fares at the University of Haifa. The latter has been researching the anti-cancer efficacy of the fungus for about 8 years and the company decided to test its use as a cure for pancreatic and colon cancer after showing better anti-cancer results than a variety of other fungi that have been tested.
Pancreatic cancer is known as one of the most violent cancers with a very low survival rate and is one of the significant causes of mortality in the Western world. Also, the FDA tends to give companies significant relief in drug development processes for this indication, such as defining the drug as an orphan drug.
Prof. Fouad Fares: “The fact that the impressive results have been achieved in cells that mimic a subtype of pancreatic cancer that is known to be highly violent reinforces the assessment that anti-cancer activity will be effective in other subtypes of pancreatic cancer as well.”
Dr. Yitzhak Angel, Kenbotek’s pharmacological consultant: “Developing a botanical drug is a challenging process and the results we have achieved give a real thread to believe that the extracts are effective and safe to use as an anti-cancer treatment for pancreatic cancer. We still have a way to prove this clinical feasibility, but we all hope .
Kenbotek CEO, Elhanan Shaked: “We have completed a significant milestone on the way to developing the botanical drug for pancreatic cancer. This is another step that brings us closer to the great vision we set for ourselves and investors about three years ago. Great, in front of the FDA. ”
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment